Cargando…

Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

BACKGROUND: Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of patients with metastases at different visceral site...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Min, Li, Jun‐Jie, Zuo, Wen‐Jia, Ji, Lei, Jiang, Yi‐Zhou, Hu, Xi‐Chun, Wang, Zhong‐Hua, Shao, Zhi‐Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797565/ https://www.ncbi.nlm.nih.gov/pubmed/31373147 http://dx.doi.org/10.1002/cam4.2453

Ejemplares similares

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
por: Li, Junjie, et al.
Publicado: (2019)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

The predictive value of serum lipids for eye metastases in male nasopharyngeal carcinoma patients
por: Xie, Zhen, et al.
Publicado: (2020)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies
por: Agrawal, Amit, et al.
Publicado: (2015)

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis
por: Gong, Yue, et al.
Publicado: (2018)

Effects of somatic alterations at pathway level are more mechanism‐explanatory and clinically applicable to quantity of liver metastases of colorectal cancer
por: Zhang, Zhong‐guo, et al.
Publicado: (2019)

Lymph Node Negative Colorectal Cancers with Isolated Tumor Deposits Should Be Classified and Treated As Stage III
por: Belt, E. J. Th., et al.
Publicado: (2010)

Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases
por: Wimmer, Kerstin, et al.
Publicado: (2016)

Growth patterns of colorectal cancer liver metastases and their impact on prognosis: a systematic review
por: Fernández Moro, Carlos, et al.
Publicado: (2018)

Helical tomotherapy for chemo‐refractory multiple liver metastases
por: Takaoka, Taiki, et al.
Publicado: (2019)

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices
por: Ma, Wei-Li, et al.
Publicado: (2022)

Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine
por: Yun, Canhua, et al.
Publicado: (2021)

The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative‐intent hepatectomy for colorectal liver metastases: A two‐center cohort study
por: Bai, Long, et al.
Publicado: (2021)

The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Systematic failure to operate on colorectal cancer liver metastases in California
por: Raoof, Mustafa, et al.
Publicado: (2020)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
por: Mori, Ryutaro, et al.
Publicado: (2014)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
por: Berrios, Kevin, et al.
Publicado: (2022)

Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
por: Seeberg, Lars Thomas, et al.
Publicado: (2017)

Use of signals of positive and negative selection to distinguish cancer genes and passenger genes
por: Bányai, László, et al.
Publicado: (2021)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Transcriptome analysis in primary colorectal cancer tissues from patients with and without liver metastases using next‐generation sequencing
por: Wang, Sen, et al.
Publicado: (2017)

Cancer‐associated stroma reveals prognostic biomarkers and novel insights into the tumour microenvironment of colorectal cancer and colorectal liver metastases
por: Brown, Kai M., et al.
Publicado: (2021)

Comprehensive analysis of cutaneous and uveal melanoma liver metastases
por: Hoefsmit, Esmee P, et al.
Publicado: (2020)

The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
por: GÜVEN, Deniz Can, et al.
Publicado: (2021)

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma
por: Tang, Jasmine YM, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_h06iq5rgch04oa1te26j877fck